Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.

Cell Cycle
Chuan-Hsiang HuangL Mario Amzel

Abstract

Phosphatidylinositide-3-kinases (PI3K) initiate a number of signaling pathways by recruiting other kinases, such as Akt, to the plasma membrane. One of the isoforms, PI3Kalpha, is an oncogene frequently mutated in several cancer types. These mutations increase PI3K kinase activity, leading to increased cell survival, cell motility, cell metabolism, and cell cycle progression. The structure of the complex between the catalytic subunit of PI3Kalpha, p110alpha, and a portion of its regulatory subunit, p85alpha reveals that the majority of the oncogenic mutations occur at the interfaces between p110 domains and between p110 and p85 domains. At these positions, mutations disrupt interactions resulting in changes in the kinase domain that may increase enzymatic activity. The structure also suggests that interaction with the membrane is mediated by one of the p85 domains (iSH2). These findings may provide novel structural loci for the design of new anti-cancer drugs.

Citations

Aug 1, 2009·Nature Reviews. Drug Discovery·Pixu LiuJean J Zhao
Sep 17, 2008·Oncogene·L Zhao, P K Vogt
Aug 18, 2010·Proceedings of the National Academy of Sciences of the United States of America·Minghao SunPeter K Vogt
Jun 11, 2009·The Journal of Biological Chemistry·Genqing LiangKirk M Druey
Oct 27, 2012·Human Molecular Genetics·Jonathan J RiosMarybeth Ezaki
Apr 25, 2012·Cancer Research·Alyssa A LeystraRichard B Halberg
Aug 31, 2010·Future Oncology·Sílvia Carvalho, Fernando Schmitt
Feb 8, 2014·Journal of Ethnopharmacology·Deok JeongJae Youl Cho
Aug 21, 2013·Archivum Immunologiae Et Therapiae Experimentalis·Eva VlugPatrick W B Derksen
Apr 20, 2013·Cancer Letters·Avaniyapuram Kannan MuruganNobuo Tsuchida
Sep 15, 2009·Bioorganic & Medicinal Chemistry Letters·Raphaël FrédérickWilliam A Denny
Feb 3, 2009·Current Opinion in Genetics & Development·Peter K VogtJonathan R Hart
Sep 4, 2015·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Nak Yoon SungJae Youl Cho
Dec 8, 2009·Cancer Cell·Bijay S JaiswalSomasekar Seshagiri
Jul 28, 2010·Laboratory Investigation; a Journal of Technical Methods and Pathology·Christina Barbara Ching, Donna Elizabeth Hansel
Aug 25, 2017·PloS One·Zachary A SzpiechRyan D Hernandez
Apr 20, 2019·Biomolecules·Antonella Papa, Pier Paolo Pandolfi
Apr 15, 2019·Cancer Metastasis Reviews·Katharine A WhiteDiane L Barber
Jan 10, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ruth NussinovHyunbum Jang
Dec 10, 2015·Journal of Biomolecular Structure & Dynamics·Namrata KalsiRituraj Purohit
Apr 19, 2019·Chemical Science·Mingzhen ZhangRuth Nussinov
Nov 15, 2018·Molecular Cancer Therapeutics·Stephanie L FrickeDustin A Deming
May 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carol O'BrienMark R Lackner
Feb 12, 2017·Molecular Cancer Research : MCR·Tyler M FoleyDustin A Deming

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.